BioSerenity

BioSerenity operates at the intersection of medical devices, electrophysiology software, diagnostics, and telemedicine rather than serving as a narrowly focused hardware vendor. Its differentiation is the integration of patient-facing EEG capture, secure clinical connectivity, remote diagnostic workflows, and AI-assisted EEG analysis in one ecosystem. Products such as Neuronaute+, IceCap, BioSerenity Cloud, B-Link, and Somnophy address acquisition and interpretation across neurology and sleep medicine, while its Large Brain Model targets faster algorithm development. The company reports a CE-certified foundation-model algorithm for normal/abnormal EEG classification, automated triage, and 98.9% specificity. Its stated footprint of more than 300 hospitals and clinics and 9,000 referring physicians suggests a clinical distribution advantage. However, the available peer-comparison records do not provide validated competitor names, market-share data, revenue, or commercial pricing, limiting direct benchmarking against companies in neurodiagnostics, wearable EEG, and remote patient monitoring. The €119.9 million funding total and 251–500 employee classification indicate a substantially scaled private medtech platform.

BioSerenity’s growth trajectory shows a transition from early-stage electrophysiology development to a scaled, vertically integrated medtech platform. The company was founded in 2014, raised a €120,000 pre-seed round that year, followed with a €3 million seed round in 2015, and secured a €15 million Series A in 2017. The clearest acceleration point was the €65 million Series B announced on Jun 19, 2019, led by Dassault Systemes, followed by additional SCOR corporate financing in 2019 and 2022. The €24 million Jolt Capital transaction in November 2023 brought cumulative funding to approximately $119.9 million and changed the company’s ownership structure. Product breadth has expanded across portable EEG, disposable caps, cloud storage, smartphone video synchronization, sleep-lab management, and remote polysomnography. In 2025, the company reported 49,000 EEGs performed and a network exceeding 300 hospitals and clinics, indicating operational adoption beyond product development. Active hiring and a 251–500 employee classification suggest continued operations, although current revenue growth, headcount progression, and post-2023 financing remain undisclosed.